LifeSci Advisors, LLC’s Post

▶️New episode of #EAUPodcasts! Want to keep up to date with screening and biopsy for prostate cancer? Dr. Roderick van den Bergh (NL) and Dr. Erik Briers (BE) discuss the dynamics of prostate cancer diagnostics, and the latest advancements in screening methods, including the updates to diagnostic algorithms that are reshaping clinical practices. Their discussion covers the role of prostate biopsies in detecting cancer, focusing on when they are most beneficial and how they impact patient outcomes. Dr. Briers also shares insights from a patients perspective, emphasising the importance of informed decision-making. 🎧Listen and learn more here 👇 https://lnkd.in/eG6ETRbB

📹 In this must-watch video, UROONCO PCa associate editor Dr. Pawel Rajwa speaks to Prof. Bertrand Tombal and Prof. Nick James on the management of synchronous metastatic hormone sensitive prostate cancer (mHSPC). They discussed treatment options such as androgen deprivation therapy (ADT) with Radium-223 or abiraterone; compared doublet and triplet therapy; examined the role of ADT; and shared their predictions in the future of mHSPC treatment. Watch the full video here 👇 https://lnkd.in/d2kWsZ5u

Did you know ProstateNow provides valuable insights into determining a patient's risk and potential treatment plans? Learn more about our ProstateNow germline test at the 2024 AUA Annual Meeting in San Antonio, TX between May 3-6! Our team will be in the exhibit hall sharing the transformative potential of ProstateNow, so stop swing by booth 823 and learn how our panel is assessing the risk of developing prostate cancer, assessing prognosis for localized prostate cancer, and how it can predict therapeutic responses for advanced prostate cancer. #AUA24

It has been established that CDK4/6i + ET is the SoC for first-line therpay in ER+/HER2-mBC. But, what are the options for second-line treatment beyond disease progression? Check out the EBCC14 Satellite Symposium led by Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo, focusing on the current and future treatment landscape for ER+/HER2- aBC! Watch summary videos where each expert discusses key topics, including: 1. ESMO metastatic breast cancer living guidelines overview 2. Impact of endocrine resistance and sensitivity 3. Benefits of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer 4.Clinical significance of ESR1 mutation and testing strategies —> https://lnkd.in/gJzpDP6i

📝We share the #Review "Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges" 🧐by Lorenzo Guidi et al. Access the full paper here▶️ https://lnkd.in/dByNUp2W Keywords: HER2-positive breast cancer; antibody-drug conjugates; trastuzumab emtansine

September is #ProstateCancerAwarenessMonth. We are committed to advancing clinical care for patients with prostate cancer, and earlier this year, we introduced p-MSI, our MSI-High predictive algorithm specifically for this patient population. In prostate cancer, MSI is uncommon and is not typically tested for, but has been reported at ~2-3% prevalence1. Learn more: https://tempus.co/47wvOE7 1. Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471-478.

🎉 We are delighted to launch our new animation showcasing the groundbreaking work we’re doing in the fight against blood cancers and solid tumors!   As the only company targeting cytidine triphosphate synthase 1 (CTPS1), the Achilles heel of cancer, Step Pharma is revolutionising the treatment landscape.   Watch this short video to find out more about our lead CTPS1 selective inhibitor, dencatistat, and our breakthrough science.   #CTPS1 #oncology #drugdiscovery

Visualization on Spatial Coordinates with visualizing the expression level of genes at the per-cell level and Plotting tumor-specific marker genes ( CEACAM5, FASN ) of Human Breast Cancer